Approved indications
Epclusa is FDA-approved to treat chronic hepatitis C virus (HCV) genotypes 1–6 in adults and children 3 years and older without cirrhosis or with compensated cirrhosis, and in combination with ribavirin for adults and children with decompensated cirrhosis.

Off-label uses
Clinicians may use Epclusa off-label in some special situations (such as certain post–liver transplant patients or unusual genotypes or co-infections) when guidelines and clinical studies support it, but these uses rely on expert consensus and study data rather than specific FDA approval.

Efficacy expectations and onset
Epclusa reduces hepatitis C viral load within days to weeks; standard therapy is usually 12 weeks, after which most patients have no detectable virus (sustained virologic response, or cure) when checked 12 weeks after treatment ends. In clinical trials, cure rates are typically above 95% across all major genotypes in people without decompensated cirrhosis when taken as directed.

Comparison to similar drugs
Compared with older interferon-based regimens, Epclusa is shorter in duration, much more effective, and far better tolerated. Compared with other modern direct-acting antiviral combinations, Epclusa is a pangenotypic option (covers all common genotypes) with high cure rates and once-daily oral dosing, making it one of the standard first-line therapies for chronic HCV.

Typical dosing and how to take
For most adults and children 3 years and older without decompensated cirrhosis, the usual dose is one Epclusa tablet (sofosbuvir 400 mg/velpatasvir 100 mg) by mouth once daily for 12 weeks, with or without food. In adults and pediatric patients with decompensated cirrhosis, Epclusa is typically given once daily with ribavirin for 12 weeks, if they can tolerate ribavirin. Pediatric dosing may use tablets or oral pellets based on body weight.

Special dosing instructions
Take Epclusa at about the same time each day. Swallow tablets whole; do not chew or crush them. If you use antacids or medicines that reduce stomach acid (such as H2 blockers or proton pump inhibitors), follow your prescriber’s specific timing and dose instructions, as these drugs can affect Epclusa absorption. Do not change or stop the medicine without talking to your prescriber, even if you feel well.

Missed dose guidance
If you miss a dose and remember within about 18 hours of your usual time, take it as soon as you remember and then take the next dose at the regular time; if it is almost time for your next dose, skip the missed dose and resume your usual schedule. Do not take two doses at once to make up for a missed dose.

Overdose
If you take more than the prescribed amount of Epclusa, contact your healthcare provider, local poison control center, or seek emergency medical care right away, especially if you feel unwell or notice unusual symptoms.

Common side effects
The most common side effects are headache, tiredness, and nausea; some people also report insomnia or mild diarrhea. These are usually mild to moderate, often begin in the first days to weeks of treatment, and tend to improve over time or after treatment ends.

Serious or rare adverse effects
Serious liver-related problems can occur in people with advanced liver disease, especially those with decompensated cirrhosis, and require urgent medical attention if symptoms such as jaundice, increasing abdominal swelling, confusion, or easy bruising worsen. Reactivation of hepatitis B virus has been reported in people with current or past hepatitis B infection, which can cause severe liver problems. Serious slowing of the heart (bradycardia) can occur when Epclusa is taken with the heart medicine amiodarone. Severe allergic reactions (such as swelling of the face or throat, trouble breathing, or severe rash) are rare but need immediate emergency care.

Warnings and precautions
Before starting Epclusa, patients are usually tested for hepatitis B and evaluated for liver function. Use in pregnancy has limited data; however, if Epclusa is taken with ribavirin, it must not be used in pregnancy and effective contraception is required for both the patient and partner during treatment and for a period after, because ribavirin can harm an unborn baby. Epclusa can generally be used in people with kidney disease, including severe impairment and dialysis, but dosing of other medicines (especially some HIV or blood pressure drugs) may need adjustment. It is approved for adults and children 3 years and older; safety and dosing are not established for younger children.

Overall safety profile
Compared with older interferon- and ribavirin-based regimens, Epclusa has a more favorable safety profile, with far fewer flu-like symptoms, mood changes, and blood-count problems, although side effects can still occur, especially when combined with ribavirin or in people with advanced liver disease.

Side effect reporting and safety updates
Patients in the United States can report side effects to the FDA MedWatch program (online or by phone) and can check the FDA website for the latest safety communications about Epclusa and other hepatitis C medications.

Drug and supplement interactions
Epclusa can interact with medicines that strongly induce certain liver and intestinal enzymes or transporters (such as rifampin, carbamazepine, phenytoin, phenobarbital, and the herbal supplement St. John’s wort), which can significantly reduce its effectiveness and are generally not recommended. Some HIV medicines (including efavirenz and certain boosted regimens containing tenofovir disoproxil fumarate) may require careful monitoring or dose adjustments due to increased tenofovir levels or reduced Epclusa levels. Certain cholesterol medicines and some other antivirals may also need adjustment or monitoring.

Food, alcohol, and acid-reducing agents
Epclusa can be taken with or without food, but large amounts of grapefruit products are generally avoided because of potential effects on drug-metabolizing enzymes. Medicines that reduce stomach acid (antacids, H2 blockers, and proton pump inhibitors) can lower velpatasvir levels; they may need to be spaced apart from Epclusa or limited to specific doses as directed by the prescriber. Alcohol does not have a known direct interaction with Epclusa, but drinking can further damage the liver, so patients with hepatitis C are usually advised to avoid or strictly limit alcohol.

Conditions and co-medications requiring caution
People with current or past hepatitis B infection need careful evaluation and monitoring because treating hepatitis C with Epclusa can lead to hepatitis B reactivation. Patients with decompensated cirrhosis or other serious liver problems need close supervision and may require dose adjustments or additional medicines such as ribavirin. Using Epclusa with amiodarone can cause serious slowing of the heart rate and is generally avoided or used only with intensive monitoring.

Monitoring needs
Before and during treatment, healthcare providers typically check blood tests, including liver function tests, viral load (HCV RNA), and, when appropriate, kidney function and hepatitis B status. Additional monitoring may be needed for people taking interacting drugs (such as certain HIV medications) or those with advanced liver disease.

Q: Does Epclusa cure hepatitis C, and how long does it take?
A: Epclusa is a curative treatment for most people with chronic hepatitis C; it is usually taken once daily for 12 weeks, and doctors typically check blood tests 12 weeks after finishing treatment to confirm the virus is no longer detectable.

Q: Can Epclusa treat all hepatitis C genotypes?
A: Yes, Epclusa is pangenotypic, meaning it is approved to treat major hepatitis C genotypes 1 through 6, though your provider will still assess your liver status and overall health to confirm it is the best option for you.

Q: What happens if I forget to take a dose of Epclusa?
A: If you remember within about 18 hours of your usual time, take the missed dose and then take the next dose at your normal time; if it is almost time for the next dose, skip the missed dose and resume your usual schedule without doubling up.

Q: Can I drink alcohol while taking Epclusa?
A: Alcohol does not directly interfere with Epclusa’s action, but it can damage your liver and may reduce the overall benefit of treatment, so most experts recommend avoiding or strictly limiting alcohol during and after therapy.

Q: Are there important medicines or supplements I should avoid with Epclusa?
A: Certain drugs and supplements, including rifampin, some seizure medicines, the herbal product St. John’s wort, and some HIV regimens, can lower Epclusa levels or increase side effects, so always review all your prescriptions, over-the-counter medicines, and supplements with your healthcare provider or pharmacist before starting Epclusa.

Storage
Store Epclusa tablets at room temperature (about 68°F to 77°F / 20°C to 25°C), in the original, tightly closed bottle with the desiccant, and protect from moisture; keep out of reach of children.

Disposal
If you no longer need Epclusa, use a drug take-back program if available; if none is available, mix unused tablets with an undesirable substance (such as used coffee grounds or cat litter), place the mixture in a sealed container, and throw it in the household trash, and remove or scratch out personal information on the prescription label.